TY - JOUR T1 - Antidepressant Response in Major Depressive Disorder: A Genome-wide Association Study JF - medRxiv DO - 10.1101/2020.12.11.20245035 SP - 2020.12.11.20245035 AU - Oliver Pain AU - Karen Hodgson AU - Vassily Trubetskoy AU - Stephan Ripke AU - Victoria S. Marshe AU - Mark J. Adams AU - Enda M. Byrne AU - Adrian I. Campos AU - Tania Carrillo-Roa AU - Annamaria Cattaneo AU - Thomas Damm Als AU - Daniel Souery AU - Mojca Z. Dernovsek AU - Chiara Fabbri AU - Caroline Hayward AU - Neven Henigsberg AU - Joanna Hauser AU - James L. Kennedy AU - Eric J. Lenze AU - Glyn Lewis AU - Daniel J. Müller AU - Nicholas G. Martin AU - Benoit H. Mulsant AU - Ole Mors AU - Nader Perroud AU - David J. Porteous AU - Miguel E. Rentería AU - Charles F. Reynolds III AU - Marcella Rietschel AU - Rudolf Uher AU - Eleanor M. Wigmore AU - Wolfgang Maier AU - Naomi R. Wray AU - Katherine J. Aitchison AU - Volker Arolt AU - Bernhard T. Baune AU - Joanna M. Biernacka AU - Guido Bondolfi AU - Katharina Domschke AU - Masaki Kato AU - Qingqin S. Li AU - Yu-Li Liu AU - Alessandro Serretti AU - Shih-Jen Tsai AU - Gustavo Turecki AU - Richard Weinshilboum AU - the GSRD Consortium AU - the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium AU - Andrew M. McIntosh AU - Cathryn M. Lewis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/15/2020.12.11.20245035.abstract N2 - Importance Antidepressants are a first line treatment for depression. However, only a third of individuals remit after the first treatment. Genetic variation likely regulates antidepressant response, yet the success of previous genome-wide association studies has been limited by sample size.Objective Gain insight into underlying biology of antidepressant response, characterize SNP-based heritability and genetic overlap with related outcomes, and evaluate out-of-sample prediction using polygenic scores.Design Genome-wide meta-analysis of antidepressant response measures, Remission and Percentage Improvement in depression scores.Setting Multiple international recruitment sites, including clinical trial and open label studies.Participants Diagnosed with Major Depressive Disorder and assessed for depressive symptoms before and after prescription of an antidepressant medication.Main Outcome(s) and Measure(s) Antidepressant response measured as Remission and Percentage Improvement.Results Genome-wide analysis of Remission (Nremit=1,852, Nnon-remit=3,299) and Percentage Improvement (N=5,218) identified no genome-wide significant variants. The heritability from common variants was significantly different from zero for Remission (h2=0.132, SE=0.056), but not Percentage Improvement (h2=-0.018, SE=0.032). Polygenic score analysis showed better antidepressant response was associated with lower genetic risk for schizophrenia, and higher genetic propensity for educational attainment. Polygenic scores for antidepressant response demonstrated weak but statistically significant evidence of out-of-sample prediction across cohorts, though results varied in external cohorts.Conclusions and Relevance This study demonstrates antidepressant response is influenced by common genetic variation, has a genetic overlap with schizophrenia and educational attainment, and provides a useful resource for future research. Larger sample sizes are required to attain the potential of genetics for understanding and predicting antidepressant response.Question What is the genetic architecture of antidepressant response, and how is it associated with other traits?Findings This genome-wide association study of antidepressant response finds Remission SNP-based heritability was significantly different from zero for Remission (h2=0.132, SE=0.056), but not Percentage Improvement (h2=-0.018, SE=0.032). Polygenic score analysis showed better antidepressant response was associated with lower genetic risk for schizophrenia, and higher genetic propensity for educational attainment.Meaning This study demonstrates antidepressant response is influenced by common genetic variation, has a genetic overlap with schizophrenia and educational attainment, and provides a useful resource for future research.Competing Interest StatementCathryn M. Lewis is on the scientific advisory board for Myriad Neuroscience. Katherine J. Aitchison has received two research grants in the last two years from Janssen Inc., Canada (fellowship grants for trainees) and provided consultancy services in the last three years for Otsuka Canada Pharmaceutical Inc., Lundbeck Canada, and HLS Therapeutics. Alessandro Serretti is or has been consultant/speaker for: Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. Andrew M. McIntosh has received research support from the Sackler Trust and speakers fees from Janssen and Illumina. Masaki Kato has received grant funding from Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker's honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithkline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Lundbeck and Ono Pharmaceutical. Qingqin S. Li is an employee of Janssen Research & Development, LLC and a shareholder in Johnson & Johnson, the parent company of the Janssen companies. Qingqin S. Li declares that, except for income received from her primary employer, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service, and there is no personal financial holding that could be perceived as constituting a potential conflict of interest.Funding StatementGSRD: The collection of this sample was supported by an unrestricted grant from Lundbeck for the Group for the Study of Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, analysis and interpretation of data. GENDEP: GENDEP was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. H. Lundbeck provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK National Institute for Health Research of the Department of Health contributed to the funding of the sample collection at the Institute of Psychiatry, London. GENDEP Illumina array genotyping was funded in part by a joint grant from the U.K. Medical research council and GlaxoSmithKline (G0701420). GENPOD: GENPOD was funded by the Medical Research Council and supported by the Mental Health Research Network, UK. The genotyping of GENPOD samples was supported by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement no. 115008 of which resources are composed of European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, Glaxo Smith Kline, and F. Hoffmann La-Roche have contributed work and samples to the project presented here. PFZ, GSK and GODS: Supported by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement no. 115008 of which resources are composed of European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, Glaxo Smith Kline, and F. Hoffmann La-Roche have contributed work and samples to the project presented here. PGRN-AMPS: PGRN-AMPS data was obtained via dbGAP (accession number: phs000670.v1.p1). Funding support for the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) was provided by the National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), through the PGRN grant to Principal Investigators R. Weinshilboum and L. Wang (U19 GM61388). Dr. D. Mrazek served as the Principal Investigator for the PGRN-AMPS study within the Mayo Clinic PGRN program. Genome-wide genotyping was performed at the RIKEN Center for Genomic Medicine, with funding provided by RIKEN. The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/. Generation Scotland: Generation Scotland is supported by the Wellcome Trust (reference 104036/Z/14/Z, 216767/Z/19/Z), The Chief Scientist Office of the Scottish Government Health Department (CZD/16/6) and the Scottish Funding Council (HR03006). Data linkage and analysis in Generation Scotland is supported by the Medical Research Council (MC_PC_17209). Douglas Biomarker Study: The genotyping of the samples was funded and generated by Janssen Research & Development, LLC PGC: We are deeply indebted to the investigators who comprise the PGC, and to the hundreds of thousands of subjects who have shared their life experiences with PGC investigators. Major funding for the PGC is from the US National Institutes of Health (U01 MH109528 and U01 MH109532). Statistical analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara. KCL: Authors OP and CML are funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The authors acknowledge support from the Medical Research Council (MR/N015746/1) and use of the research computing facility at Kings College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the NIHR Maudsley BRC, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guys & St. Thomas Charity (TR130505). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies recieved ethical approval from the relevant ethics committee or institutional review board. The ethical details of each study are given in the Supplementary Materials in the Ethical Information table, p3-5.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to summary statistics will be made available through the Psychiatric Genomics Consortium on publication of the peer-reviewed manuscrtip. https://www.med.unc.edu/pgc/ ER -